Off-label use of rituximab in dermatology: pemphigus treatment
Since its approval in 1997 by the FDA (United States Food and Drug Administration), rituximab has been used for certain B-cell lymphomas and treatment-resistant rheumatoid arthritis. Nevertheless, over the past 14 years, many case reports have demonstrated the efficacy of off-label rituximab in several dermatological inflammatory conditions. This study describes two cases of pemphigus vulgaris and two cases of pemphigus foliaceous that were treated with rituximab at 375 mg/m2 once a week for 4 weeks, and that responded well to treatment.
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Digital revista |
| Language: | English |
| Published: |
Sociedade Brasileira de Dermatologia
2013
|
| Online Access: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962013000400676 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|